非子宫内膜样子宫内膜癌分期淋巴结清扫术的生存意义
该研究基于美国国家癌症数据库2010至2013年7250例临床I期浆液性癌、透明细胞癌或癌肉瘤患者,采用倾向评分加权多因素Cox回归分析,发现盆腔淋巴结清扫与死亡风险降低相关(HR=0.65,95%CI:0.59-0.71),浆液性癌中盆腔+腹主动脉旁淋巴结清扫较单纯盆腔清扫进一步降低死亡风险(HR=0.85,95%CI:0.79-0.91)。
要点
- 盆腔淋巴结清扫与未清扫相比,死亡风险降低(HR=0.65,95%CI:0.59-0.71)。
- 浆液性癌中盆腔+腹主动脉旁清扫较单纯盆腔清扫,死亡风险降低(HR=0.85,95%CI:0.79-0.91)。
- 清扫淋巴结数>15枚与死亡风险降低独立相关(HR=0.86,95%CI:0.77-0.96)。
核心结论
- 非子宫内膜样子宫内膜癌患者中,淋巴结清扫与生存获益相关。
- 浆液性癌患者中,在盆腔淋巴结清扫基础上加做腹主动脉旁淋巴结清扫可能获益最大。
- 系统性淋巴结清扫可能通过检出并显微镜下减灭隐匿病灶而与生存获益相关。
研究设计与样本
- 回顾性队列研究,数据来自美国国家癌症数据库(National Cancer Database)。
- 纳入2010年至2013年接受子宫切除术的临床I期浆液性癌、透明细胞癌或癌肉瘤患者,共7250例。
- 采用倾向评分加权多因素Cox回归模型评估死亡风险比(HR),并按组织学亚型进行亚组分析。
主要发现
- 930例(13%)未行淋巴结清扫,2177例(30%)仅行盆腔淋巴结清扫,4143例(57%)行盆腔+腹主动脉旁淋巴结清扫。
- 倾向评分加权分析中,盆腔淋巴结清扫较未清扫与死亡风险降低相关(HR=0.65,95%CI:0.59-0.71)。
- 浆液性癌患者中,盆腔+腹主动脉旁淋巴结清扫较单纯盆腔淋巴结清扫与死亡风险降低相关(HR=0.85,95%CI:0.79-0.91)。
- 清扫淋巴结数>15枚与死亡风险降低独立相关(HR=0.86,95%CI:0.77-0.96);在淋巴结阳性患者中该关联仍存在(HR=0.78,95%CI:0.63-0.95)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To determine, in patients with non-endometrioid endometrial carcinoma, 1) survival benefit associated with pelvic lymphadenectomy (LND), 2) survival benefit for para-aortic lymphadenectomy performed in addition to pelvic lymphadenectomy, and 3) association between number of lymph nodes removed and survival. METHODS: Patients with clinical stage I serous carcinoma, clear cell carcinoma, or carcinosarcoma who underwent hysterectomy from 2010 to 2013 were identified from the National Cancer Database. Hazard ratio (HR) for death was assessed using propensity score-weighted multivariable Cox regression models. Subgroup analyses assessed for differences in risk of death among histologic subtypes. RESULTS: 7250 patients met study criteria. 930 (13%) did not undergo LND; 2177 (30%) underwent pelvic LND alone; 4143 (57%) underwent pelvic+para-aortic LND. On propensity score-weighted analysis, pelvic LND was associated with decreased risk of death (HR=0.65, 95% CI: 0.59-0.71) compared to no LND. Pelvic+para-aortic LND was associated with decreased risk of death (HR=0.85, 95% CI: 0.79-0.91) compared to pelvic LND for patients with serous carcinoma. Removal of >15 nodes was independently associated with decreased HR for death (HR=0.86, 95% CI: 0.77-0.96); this association persisted when analysis was limited to patients with node-positive disease (HR=0.78, 95% CI: 0.63-0.95). CONCLUSIONS: LND is associated with survival benefit in patients with non-endometrioid endometrial cancers. Addition of para-aortic LND to pelvic LND may be most beneficial for patients with serous carcinoma. Systematic lymphadenectomy may be associated with survival benefit through detection and microscopic cytoreduction of occult disease.
引用
- Venigalla S, Chowdhry AK, Shalowitz DI, et al. Survival implications of staging lymphadenectomy for non-endometrioid endometrial cancers. Gynecol Oncol. 2018. PMID: 29559170. doi:10.1016/j.ygyno.2018.03.046
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。